This study tested the hypothesis that treatment with a nonsteroidal anti-inflammatory drug will not alter the hypotensive effect of a dihydropyridine calcium channel antagonist. Fifteen essential hypertensives (ages 58-80 years) had a supine diastolic blood pressure (DBP) < 100 mmHg after 4 weeks monotherapy with nitrendipine 5-20 mg twice daily. They entered a double-blind randomised crossover study in which the addition of indomethacin 25 mg three times daily was compared with placebo in treatment phases each of 4 weeks duration. Subjects were seen weekly and measurements in the last 2 weeks of each phase were compared. Supine blood pressure (mean ± SE) was higher in the indomethacin phase (158 ± 4/80 ± 2) than in the placebo phase (154 ± 4/76 ± 3) (p < 0.01 for DBP). In 6/15 (40% of subjects the increase in supine diastolic blood pressure with indomethacin was >5 mmHg. Plasma urea was also increased in the indomethacin phase: 7.6 ± 0.6 mmol/1 compared with placebo: 6.3 ± 0.5 mmol/1 (p < 0.001). The study has demonstrated that concurrent treatment with the NSAID indomethacin impairs the blood pressure lowering effect of the dihydropyridine calcium channel antagonist nitrendipine. This increase in blood pressure with indomethacin in subjects treated with nitrendipine may represent either an independent pressor effect of indomethacin or a reduced vasodilator prostanoid contribution to the hypotensive effect of nitrendipine. This blood pressure increase may be sufficient to interfere significantly with clinical blood pressure control in some subjects.
- Calcium channel antagonists
- Essential hypertension
- Non-steroidal anti-inflammatory drugs